Scope
This focused adult ADPKD summary covers diagnosis and prognosis, blood-pressure management, kidney cyst infection, selection and monitoring for tolvaptan, hydration, selected liver and intracranial complications, transplantation and pregnancy planning. The 2025 KDIGO guideline emphasizes shared decisions and individualized assessment of disease progression, treatment burden and safety.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Establish diagnosis and progression risk
- For adults at risk of ADPKD, begin screening with abdominal ultrasound interpreted alongside family history, kidney function and comorbidities (1B). Counsel before and after imaging or genetic screening; MRI, CT and/or genetic testing may resolve an uncertain diagnosis. [1]
- Genetic testing is not required for an initially typical ADPKD presentation, but is particularly informative with equivocal imaging or negative/unknown family history and can help select living-related donors. Negative or uncertain genetic results do not exclude inherited ADPKD in a typical clinical presentation. [1]
- Use the Mayo Imaging Classification to predict kidney-function decline and timing of kidney failure (1B). Exclude atypical imaging subclasses 2A/2B and, when genotype is known, pathogenic variants outside PKD1/PKD2. Age-related eGFR and longitudinal decline can also help identify rapid progression. [1]
Treat blood pressure in the correct population
- In nonpregnant adults with ADPKD aged 18–49, CKD G1–G2 and blood pressure above 130/85 mmHg, KDIGO recommends a home-measured target of 110/75 mmHg or lower if tolerated (1D). Between above 110/75 and below 130/85 mmHg, individualize treatment through shared decision-making. [1]
- In nonpregnant adults with ADPKD aged at least 50 and CKD G1–G5, KDIGO suggests a mean systolic target below 120 mmHg if tolerated, measured by standardized office technique (2C). Home or ambulatory measurements should complement standardized office readings (2B). [1]
- For high blood pressure in ADPKD, use an ACE inhibitor or ARB first line (1C); avoid combining ACE inhibitors, ARBs or direct renin inhibitors (1B). Investigate resistant hypertension requiring at least 3 drugs for another cause, and investigate high-grade proteinuria for coexisting kidney disease. [1]
Distinguish pain, infection and other complications
- Investigate chronic flank, abdominal or lumbar pain for non-ADPKD causes and complications such as infection or stones. Begin with nonpharmacological, noninvasive measures; use stepwise medication if these are insufficient. Refractory chronic kidney pain warrants a multidisciplinary approach. [1]
- In ADPKD, fever plus acute abdominal/flank pain and raised white cells and/or CRP warrants investigation for kidney cyst infection. Obtain urine culture before UTI antibiotics and blood cultures for suspected upper UTI or cyst infection; distinguish infection from cyst haemorrhage or stones. [1]
- For ADPKD kidney cyst infection, KDIGO suggests 4–6 weeks of antibiotics rather than a shorter course (2D). If possible use a lipid-soluble agent, such as a fluoroquinolone or trimethoprim–sulfamethoxazole. Antibiotic allergy, resistance and kidney function require individualized prescribing. [1]
Select and monitor tolvaptan carefully
- Initiate tolvaptan in adults with ADPKD, eGFR at least 25 mL/min/1.73 m2 AND risk of rapid progression (1B). The source uses Mayo classes 1C–1E or historical eGFR decline at least 3 mL/min/1.73 m2/year; class 1C requires case-by-case judgment. Exclude alternative causes of eGFR loss and individualize initiation above age 55. [1]
- Before tolvaptan, review contraindications and drug interactions. Absolute contraindications include pregnancy/planned pregnancy or breastfeeding, volume-depletion risk, inability to perceive/respond to thirst, uncorrected hypernatraemia, urinary obstruction, strong CYP3A inhibitors and significant liver disease other than polycystic liver disease. [1]
- For eligible adults with ADPKD starting tolvaptan, use 45 mg on waking and 15 mg 8 hours later, titrating gradually to accommodate aquaresis. The general target is 90 mg on waking plus 30 mg 8 hours later, unless intolerable or contraindicated by interactions. [1]
- In ADPKD, tolvaptan requires baseline AST, ALT and total bilirubin and mandatory liver tests monthly for the first 18 months, then every 3 months. Some regulators also require tests at 2 and 4 weeks in the first month; follow local product instructions for abnormal results. [1]
- Explain tolvaptan-related thirst, polyuria and nocturia and the need to replace urinary water losses. Provide a sick-day plan and interrupt treatment immediately with volume depletion, inability to replace water losses or inability to monitor liver tests; skip doses during vomiting, diarrhoea or limited water access. [1]
- After tolvaptan has already been started, reaching age above 55 or an eGFR below 25 mL/min/1.73 m2 does not by itself require stopping. Individualize withdrawal near kidney replacement therapy and stop before it begins; stop before pregnancy and during breastfeeding. [1]
Support kidney and extrarenal care
- For ADPKD without tolvaptan and eGFR at least 30 mL/min/1.73 m2, KDIGO suggests water intake of at least 2–3 litres daily spread through the day, if safe (2D). First assess fluid-retention and hyponatraemia risk. With eGFR below 30 or a contraindication to high intake, drink to thirst and/or follow individualized advice. [1]
- Do not use SGLT2 inhibitors to slow eGFR decline in ADPKD. KDIGO recommends against metformin specifically to slow progression in people without diabetes (1B), and advises against ketogenic interventions without further controlled-trial evidence. These statements concern ADPKD treatment, not unrelated established indications. [1]
- Manage symptomatic polycystic liver disease in an expert centre. For ADPKD with markedly enlarged polycystic livers and severe volume-related symptoms, KDIGO recommends long-acting somatostatin analogues (1B). Assess symptom/volume benefit after 6–12 months and discontinue if ineffective; monitor gastrointestinal, gallstone, glucose and bradycardic adverse effects. [1]
Discuss intracranial aneurysm risk and screening
- Inform adults with ADPKD of increased intracranial-aneurysm and subarachnoid-haemorrhage risk (1C). Teach that a severe sudden headache peaking within seconds to a minute requires immediate medical attention. [1]
- Screen for intracranial aneurysm in adults with ADPKD and personal subarachnoid haemorrhage or family history of aneurysm, subarachnoid haemorrhage or unexplained sudden death, if treatment-eligible with reasonable life expectancy (1D). Discuss screening in de novo/uncertain-family-history cases; informed lower-risk patients who prefer it should have access. [1]
- When screening for intracranial aneurysm in ADPKD, prefer time-of-flight MRA without gadolinium; high-resolution CTA is an alternative. After a negative screen in a high-risk person, individualize repeat screening, possibly every 5–10 years. Identified aneurysms warrant expert multidisciplinary assessment. [1]
Plan transplantation and pregnancy
- Kidney transplantation is preferred for ADPKD kidney failure, ideally a pre-emptive living-donor transplant. Exclude ADPKD in potential related donors. Native nephrectomy before transplantation is not routine: KDIGO suggests it only for specific indications when benefit outweighs risk (2C), with shared multidisciplinary planning. [1]
- Offer reproductive-age men and women with ADPKD multidisciplinary preconception counseling and available reproductive options. Stop tolvaptan and ACE inhibitors/ARBs before pregnancy; do not restart tolvaptan until breastfeeding is complete. [1]
- Pregnancy with ADPKD warrants specialist multidisciplinary care and monitoring for pre-eclampsia and kidney complications. Perform monthly urinalysis and treat confirmed bacteriuria even without symptoms. The source advises aspirin 75–150 mg daily from week 12 through week 36 to reduce pre-eclampsia risk. [1]
Limitations and use
- This covers selected adult recommendations, not the complete guideline. Childhood screening and treatment, exact diagnostic cyst-count criteria, detailed liver procedures, stone and gout regimens, and complete transplant or reproductive protocols are outside scope.
- Blood-pressure targets below are for nonpregnant adults in the stated age and CKD groups. The source provides separate pregnancy care; do not apply the intensive young-adult target during pregnancy.
- Tolvaptan requires specialist selection, full contraindication and interaction review, reliable hydration and mandatory liver monitoring. This summary does not replace local product information or establish a liver-injury rechallenge protocol. Hydration alone has limited evidence for slowing kidney disease progression.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Autosomal dominant polycystic kidney disease
Selected recommendation material consulted
Publication details
- Issuing organisation
- KDIGO
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.